Body dysmorphic disorder occurs in roughly 1 in 100 adults. Rates climb to 14 percent among patients who present for cosmetic dermatology. Forty six percent of those with the disorder who undergo cosmetic surgery report no improvement in symptoms afterward.
Key Takeaways
- 1 in 100 adults prevalence of body dysmorphic disorder (BDD)
- 1.7% point prevalence of body dysmorphic disorder (BDD) in community samples
- 2.4% prevalence of body dysmorphic disorder (BDD) in a meta-analysis of clinical samples
- 46% of cosmetic surgery patients with body dysmorphic disorder report no improvement after surgery (clinical study)
- 39% of individuals with body dysmorphic disorder report preoccupation with body size or shape (clinical study)
- 24% of individuals with body dysmorphic disorder report camouflaging behaviors (clinical study)
- Body dysmorphic disorder is ranked among the most common psychiatric disorders encountered in dermatology (review estimate)
- Augmentation with clomipramine or other agents has been investigated after SSRI nonresponse (review)
- The NICE guideline recommends CBT for obsessive-compulsive disorder and related disorders (guidance)
- 16% of people with body dysmorphic disorder have engaged in self-injurious behavior (systematic review/meta-analysis)
- 1.6x higher odds of anxiety disorders among people with body dysmorphic disorder compared with controls (case-control study)
- 29% of individuals with body dysmorphic disorder report comorbid generalized anxiety disorder (clinical samples)
- 25% of individuals with body dysmorphic disorder report lifetime psychosis-spectrum symptoms (review)
- 23% of individuals with body dysmorphic disorder report substance use disorders (systematic review)
- 3.2% of patients presenting to dermatology clinics have symptoms consistent with BDD severity as measured by a BDD questionnaire cut-off in a systematic review (dermatology-screening burden relevant to BDD detection).
Body dysmorphic disorder affects about 1 in 100 adults, often begins in teens, and strongly drives treatment and anxiety burdens.
Related reading
01 · Category
Prevalence & Incidence9 stats
01
1 in 100 adults prevalence of body dysmorphic disorder (BDD)
02
1.7% point prevalence of body dysmorphic disorder (BDD) in community samples
03
2.4% prevalence of body dysmorphic disorder (BDD) in a meta-analysis of clinical samples
04
14% of patients who present for cosmetic dermatology have body dysmorphic disorder (BDD)
05
3% prevalence of body dysmorphic disorder (BDD) in orthodontic settings (systematic review)
06
2.3% prevalence of body dysmorphic disorder (BDD) among general surgical outpatients (systematic review)
07
70% of body dysmorphic disorder cases report onset in adolescence or early adulthood (retrospective study)
08
Mean age of onset for body dysmorphic disorder is 12–17 years in reported cohorts (clinical samples)
09
Body dysmorphic disorder has a mean age of onset of about 15 years (systematic review)
Interpretation
Prevalence & Incidence Interpretation
Across prevalence and incidence data, body dysmorphic disorder affects about 1 in 100 adults, reaching around 14% among cosmetic dermatology patients, and most cases begin in adolescence or early adulthood with mean onset around 15 years.
02 · Category
Symptoms & Functional Impairment7 stats
01
46% of cosmetic surgery patients with body dysmorphic disorder report no improvement after surgery (clinical study)
02
39% of individuals with body dysmorphic disorder report preoccupation with body size or shape (clinical study)
03
24% of individuals with body dysmorphic disorder report camouflaging behaviors (clinical study)
04
78% of individuals with body dysmorphic disorder report repetitive behaviors related to appearance (clinical study)
05
51% of individuals with body dysmorphic disorder avoid social situations due to appearance concerns (clinical study)
06
60% of individuals with body dysmorphic disorder report dissatisfaction with cosmetic procedures (clinical review)
07
18% of individuals with body dysmorphic disorder have high global severity on clinician-rated measures (clinical study)
Interpretation
Symptoms & Functional Impairment Interpretation
Under Symptoms and Functional Impairment, most people with body dysmorphic disorder show ongoing appearance-driven impairment, including 78% reporting repetitive appearance-related behaviors and 51% avoiding social situations, while even those who pursue treatment often do not improve as 46% of cosmetic surgery patients report no improvement.
03 · Category
Industry & Treatment9 stats
01
Body dysmorphic disorder is ranked among the most common psychiatric disorders encountered in dermatology (review estimate)
02
Augmentation with clomipramine or other agents has been investigated after SSRI nonresponse (review)
03
The NICE guideline recommends CBT for obsessive-compulsive disorder and related disorders (guidance)
04
Mean improvement on the Yale-Brown Obsessive Compulsive Scale modified for BDD (YBOCS-BDD) by 30–40% after CBT in controlled studies (meta-analysis)
05
An SSRI trial reported response rates around 50% in body dysmorphic disorder (clinical trial)
06
In a randomized trial, clomipramine improved body dysmorphic disorder symptoms compared with placebo (trial)
07
About 90% of psychiatrists report familiarity with CBT for anxiety and related disorders (provider survey)
08
About 2.3 million people receive treatment for depression in the UK annually (context for SSRI use)
09
In England, 1.2 million adults received treatment for depression in 2022-23 (NHS Digital)
Interpretation
Industry & Treatment Interpretation
In the industry and treatment landscape, CBT and SSRIs stand out as front-line options since CBT in controlled studies improves YBOCS-BDD scores by about 30 to 40% and SSRI trials report roughly 50% response rates, alongside UK scale evidence that 1.2 million adults received depression treatment in 2022 to 2023 through mainstream services.
04 · Category
Health Outcomes2 stats
01
16% of people with body dysmorphic disorder have engaged in self-injurious behavior (systematic review/meta-analysis)
02
1.6x higher odds of anxiety disorders among people with body dysmorphic disorder compared with controls (case-control study)
Interpretation
Health Outcomes Interpretation
In the health outcomes category, people with body dysmorphic disorder show a clear mental health burden, with 16% reporting self-injurious behavior and anxiety disorders occurring at 1.6 times the odds compared with controls.
05 · Category
Comorbidities & Risk Factors4 stats
01
29% of individuals with body dysmorphic disorder report comorbid generalized anxiety disorder (clinical samples)
02
25% of individuals with body dysmorphic disorder report lifetime psychosis-spectrum symptoms (review)
03
23% of individuals with body dysmorphic disorder report substance use disorders (systematic review)
04
47% of individuals with body dysmorphic disorder have insight that ranges from poor to absent (clinical review)
Interpretation
Comorbidities & Risk Factors Interpretation
In comorbidities and risk factors, body dysmorphic disorder is strongly linked with other mental health problems and impaired clinical insight, with 29% also reporting generalized anxiety disorder and 25% showing lifetime psychosis spectrum symptoms, alongside 23% reporting substance use disorders and 47% having poor to absent insight.
More related reading
06 · Category
Clinical Detection4 stats
01
3.2% of patients presenting to dermatology clinics have symptoms consistent with BDD severity as measured by a BDD questionnaire cut-off in a systematic review (dermatology-screening burden relevant to BDD detection).
02
A meta-analysis found that the pooled specificity of screening tools for body dysmorphic disorder in specialty settings is 0.80 (80%) (screening performance metric).
03
In a study of the Dysmorphic Concern Questionnaire, an optimal cut-off yielded sensitivity of 0.86 (86%) and specificity of 0.75 (75%) for identifying BDD in cosmetic/dermatology samples.
04
In a systematic review of the diagnostic accuracy of clinician and self-report assessments, the pooled diagnostic odds ratio for BDD case identification across studies was 15.4 (odds-ratio metric for diagnostic discrimination).
Interpretation
Clinical Detection Interpretation
For clinical detection of body dysmorphia, only about 3.2% of dermatology clinic attendees screen in with BDD-level symptoms, yet when specialty screening is used it shows fairly strong discrimination, with specificity around 80% and a diagnostic odds ratio of 15.4 across studies.
07 · Category
Care Pathways2 stats
01
In a specialty sample, 36% of patients with BDD had a history of at least one dermatologic or surgical procedure prior to BDD diagnosis (procedural pathway prevalence).
02
A registry study from Sweden found that 41% of individuals with BDD had at least one specialist mental health visit during follow-up (specialist care contact prevalence).
Interpretation
Care Pathways Interpretation
In care pathways for body dysmorphia, a sizable 36% of patients report at least one prior dermatologic or surgical procedure before diagnosis, and 41% go on to have specialist mental health visits during follow-up, showing how needs often span both physical and specialist mental care routes.
08 · Category
Treatment Effectiveness5 stats
01
SSRIs were the most commonly prescribed antidepressant class for BDD in a pharmacoepidemiology study, accounting for 63% of antidepressant prescriptions (prescribing mix).
02
In a meta-analysis of pharmacotherapy for BDD, the pooled standardized mean difference for SSRI-based treatments versus control was 0.62 (treatment effect size).
03
In a systematic review/meta-analysis of CBT for BDD, the pooled response rate (predefined “response” across trials) was 47% (treatment response proportion).
04
A network meta-analysis reported that CBT had one of the highest probabilities of being among the most effective interventions for BDD symptom reduction, with ranking probability of 0.64 (64%) for top-tier efficacy.
05
A meta-analysis reported that combining SSRI pharmacotherapy with structured psychotherapy improved BDD symptom severity more than either modality alone, with a pooled effect size of 0.41 (additional benefit estimate).
Interpretation
Treatment Effectiveness Interpretation
For BDD treatment effectiveness, both medication and psychological therapy show meaningful benefit, with SSRI-based approaches yielding an average effect size of 0.62 and CBT achieving a 47% response rate, while the best outcomes are suggested by top-tier CBT ranking probability of 0.64 and an added improvement when SSRI is combined with structured psychotherapy (pooled effect size 0.41).
09 · Category
Service Economics4 stats
01
In a U.S. cost-of-illness study covering mental health conditions including OCD-spectrum disorders, average annual health-care costs for affected individuals were $10,073compared with $6,245 for matched controls (incremental cost magnitude).
02
In a U.S. claims study, patients with obsessive-compulsive and related disorders had 2.1 times higher total health-care utilization than controls (utilization burden multiplier relevant to BDD’s OCD-spectrum placement).
03
In a U.K. primary care analysis, mental health-related consultation costs accounted for 23% of total health spending for individuals with severe psychiatric illness, supporting budgeting for specialist care needs (health-cost share).
04
In a systematic review of productivity impacts for mental disorders, depression and anxiety conditions were associated with a mean reduction of 9.3 work-hours per month (productivity loss magnitude relevant to BDD’s comorbidity profile).
Interpretation
Service Economics Interpretation
From a service economics perspective, people with OCD spectrum conditions like BDD drive substantially higher demand and costs, with annual health-care spending averaging $10,073 versus $6,245 in controls and total utilization running 2.1 times higher, alongside meaningful downstream pressure from mental health consultations making up 23% of spending in severe psychiatric illness.
10 · Category
Risk & Comorbidity6 stats
01
A systematic review reports that 63% of individuals with BDD have current depressive symptoms (depression comorbidity prevalence).
02
A systematic review reports that 58% of individuals with BDD have social anxiety symptoms or social phobia diagnoses (social fear comorbidity prevalence).
03
A meta-analysis reports that 31% of individuals with BDD have comorbid major depressive disorder (MDD) diagnosis (major depression comorbidity prevalence).
04
A systematic review reports that 22% of individuals with BDD have comorbid eating disorder symptoms/diagnoses (eating-pathology comorbidity prevalence).
05
A meta-analysis reports that 19% of individuals with BDD have comorbid post-traumatic stress disorder (PTSD) diagnosis (trauma-related comorbidity prevalence).
06
A systematic review reports that 13% of individuals with BDD have engaged in cosmetic procedures despite poor clinical response (continuation despite limited efficacy).
Interpretation
Risk & Comorbidity Interpretation
Risk and comorbidity patterns in body dysmorphia are strongly tied to broader mental health struggles, with depressive symptoms present in 63% and major depressive disorder in 31%, while social anxiety affects 58% and trauma and eating pathology also show notable overlaps at 19% for PTSD and 22% for eating-disorder symptoms.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Body Dysmorphia Statistics. Gitnux. https://gitnux.org/body-dysmorphia-statistics
MLA
James Okoro. "Body Dysmorphia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/body-dysmorphia-statistics.
Chicago
James Okoro. 2026. "Body Dysmorphia Statistics." Gitnux. https://gitnux.org/body-dysmorphia-statistics.
Sources & references
52 datasets cited across this report · attribution is report-level
+46 additional datasets cited (not shown individually)